Citation(s)
- Sarina Anne Piha-Paul, Christine L
Hann, Christopher A. French, Sophie Cousin, Irene Brana Garcia, Philippe Cassier, Victor Moreno, Johann De Bono, Sara D. Harward, Geraldine Ferron-Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J. Parr, Rabinder K. Prinjha, Christopher L. Carpenter, John Hilton, David S Hong, Naomi B. Haas, Mark Markowski, Arindam Dhar, Peter O'Dwyer, Geoffrey I. Shapiro. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum. 2019
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
Details for clinical trial NCT01587703
